Pharmaceutical

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue

Days after competitor Novo Nordisk posted underwhelming Wegovy sales, Eli Lilly cited “strong performance” for Zepbound and Mounjaro.

Aug 11, 2024 - 04:00
Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue
Days after competitor Novo Nordisk posted underwhelming Wegovy sales, Eli Lilly cited “strong performance” for Zepbound and Mounjaro.
Read the original article

Tags:

Previous Article

NICE supports Theramex’s Eladynos for post-menopause osteoporosis

Next Article

AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: FDA panel recommends first OTC birth control pill; Senate hearing on insulin costs satisfies no one

STAT+: Pharmalittle: FDA panel recommends first OTC bir...

May 11, 2023

Lyra Therapeutics gets grant for coated scaffold for tr...

Aug 23, 2024

White House announces new plan to address the growing threat of xylazine in overdose crisis

White House announces new plan to address the growing t...

Jul 12, 2023